Bronnen & referenties

1 Shapley M, Jordan K, Croft PR. An epidemiological survey of symptoms of menstrual loss in the community. The British Journal of General Practice: the journal of the Royal College of General Practitioners, 2004;54(502):359-363. Bekijk bron.

2 Schoep ME, Nieboer TE, van der Zanden M, Braat DDM, Nap AW. The impact of menstrual symptoms on everyday life: a survey among 42,879 women, American Journal of Obstetrics and Gynecology (2019). doi: 10.1016/j.ajog.2019.02.048.

3 Schoep ME, Adang, EMM, Maas JWM, et al; Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32,748 women, BMJ Open (2019). doi: 10.1136/bmjopen-2018-026186.

4 Heavy Periods, online survey among 1,004 women who have experienced heavy periods in the past 3 years (18+), 14th to 18th September 2018, 24 september 2018, 3 Monkeys Zeno for Hologic Benelux. Bekijk bron

5 Meijer L J, Bruinsma AC, Pameijer AS, Hehenkamp WJ, Janssen CA, Burgers JS, De Vries CJ (2014). NHG-Standaard Vaginaal bloedverlies (derde herziening). Huisarts Wet, 57, 406-14.

6 Royal College of Obstetricians and Gynaecologists. National heavy menstrual bleeding audit. Final Report First annual report. July 2014.

7 PhilMed Zorgmarketing, januari 2011.

8 Willemsen WNP, De Kruif JH, Velthausz MBF, Meelen BTHM (2000). Myomen en vruchtbaarheid. Nederlands Tijdschrift voor Geneeskunde. 144(17):789-791.

9 Endometriose Stichting (bezocht op 9-3-2019).

10 Stichting PCOS Nederland (bezocht op 9-3-2019).

11, Baarmoeder (bezocht op 3-9-2019).

12, Baarmoederhalskanker (bezocht op 3-9-2019).

13 Centers for Disease Control and Prevention. Heavy menstrual bleeding. Accessed April 07, 2017.

14 Knol, H. M. (2012). Determinants of bleeding in obstetrics and gynaecology. Groningen: s.n. (opgehaald van

15 Nederlandse Vereniging van Hemofilie-Patiënten (NVHP), Over Hemofilie (bezocht op 1-7-2019),

16 Nederlandse Vereniging van Hemofilie-Patiënten (NVHP), Vrouwen en Stollingsstoornissen (bezocht op 1-7-2019),

17 WIN-STuDIE, D. E. (2014). De ziekte van von Willebrand in Nederland. NED TIJDSCHR GENEESKD, 158, A6518 (opgehaald van, 29-7-2019).

18 ACOG Committee on Practice Bulletins. ACOG Practice Bulletin: Management of Anovulatory Bleeding. Int J Gynecol Obstet. 2001;72(3):263-271. Bekijk bron.

19 Busfield RA, Farquhar CM, Sowter MC, et al. A Randomised Trial Comparing the Levonorgestrel Intrauterine System and Thermal Balloon Ablation for Heavy Menstrual Bleeding. BJOG. 2006;113(3):257263.

20 Cooper KG, et al. A randomised comparison of medical and hysteroscopic management in women consulting a gynaecologist for treatment of heavy menstrual loss. Br J Obstet Gynaecol. 1997; 104:1360-1366.

21 Cooper KG, Jack SA, Parkin DE, Grant AM. Five-Year Follow-up of Women Randomised to Medical Management or Transcervical Resection of the Endometrium for Heavy Menstrual Loss: Clinical and Quality of Life Outcomes. Br J Obstet Gynaecol. 2001;108(12):1222-1228.

22 Clinical and Quality of Life Outcomes. Br J Obstet Gynaecol. 2001;108(12):1222-1228.

23 Decherney AH, et al. Current Obstetric & Gynecologic Diagnosis & Treatment, ninth edition. New York, NY: McGraw-Hill Medical; 2003.

24 Hurskainen R, et al. Clinical outcomes and costs with the levonorgestrel releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA. 2004; 291:1456-1463.

25 The American College of Obstetricians and Gynecologists. Frequently Asked Questions, Gynecologic Problems. ACOG. 2011; FAQ162.

26 Singh RH, et al. Hormonal management of abnormal uterine bleeding. Clin Obstet Gynecol. 2005; 48:337-352. 11. Decherney AH, et al. Current Obstetric & Gynecologic Diagnosis & Treatment, ninth edition. New York, NY: McGraw-Hill Medical; 2003.

27 Yasmin Prescribing Information. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2007.

28 Backman T, Huhtala S, Blom T, Luoto R, Rauramo I, Koskenvuo M. Length of use and symptoms associated with premature removal of levonorgestrel intrauterine system: a nationwide study of 17,360 users. BJOG 2000; 107:335-9.

29 Istre O, et al. Treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. Fertil Steril. 2001; 76:304-309.

30 Mirena Prescribing Information. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2007.

31 ACOG Committee on Practice Bulletins. ACOG Practice Bulletin: Endometrial Ablation. Obstet Gynecol 2007;109(5)1233-48.

32 Cooper J, et al. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2002; 9:418-428. Bekijk bron.

33 Clinical and Quality of Life Outcomes. Br J Obstet Gynaecol. 2001;108(12):1222-1228.

34 Gallinat A. An Impedance-Controlled System for Endometrial Ablation: Five-Year Follow-up of 107 Patients. JReprod Med. 2007;52(6):467-472. Bekijk bron.

35 Gimpelson RJ. Ten-year literature review of global endometrial ablation with the NovaSure device. Int J Womens Health. 2014;6:269-280.

36 NovaSure® Instructions for Use. Bedford, MA: Hologic, Inc.

37 American Society for Reproductive Medicine. Uterine Fibroids: A Guide for Patients. Accessed Feb 2019.

38 Advancing minimally invasive gynaecology worldwide. AAGL Practice Report: Practice Guidelines for the Diagnosis and Management of Endometrial Polyps. J Minim Invasive Gynecol. 2012; 19:3-10.

39 Ayas S, Gurbuz A, Eskicirak E, et al. Follow-up and hysteroscopic evaluation of the uterine cavity after hysteroscopic polypectomy. SAJOG. 2011;17(1):10-13.

40 Clark TJ et al. A randomised controlled trial of outpatient versus inpatient Polyp Treatment (OPT) for abnormal uterine bleeding. Health technology assessment. 2015; 19(61).

41 Emanuel MH, Wamsteker K, Hart AA; et al. Long-term results of hysteroscopic myomectomy for abnormal uterine bleeding. Obstet Gynecol. 1999; 93:743-748 (II-2).

42 Flake GP, et al. Etiologiy and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003; 111(8):1037–54.

43 Guys & St Thomas NHS Trust; Patient information: Surgery to remove polyps or fibroids: Accessed Feb 2019.

44 Jansen FW, Vredevoogd CB, van Ulzen K; et al. Complications of hysteroscopy: a perspective, multicenter study. Obstet Gynecol. 2000 Aug; 96(2):266-270.

45 McIlwaine P, McElhinney B, Karthigasu KA, Hart R, A Prospective Study of the Use of the MyoSure Resectoscope to Manage Endometrial Polyps in an Outpatient Setting. The Australian and New Zealand Journal of Obstetrics and Gynaecology. October 2015.

46 NHS Fibroid Overview: Accessed Feb 2019.

47 Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007; 87(4):725-36.

48 Rubino RJ, Lukes AS, Twelve Month Outcomes for Patients Undergoing Hysteroscopic Morcellation of Uterine Polyps and Myomas in an Office or Ambulatory Surgical Center. J Minim Invasive Gynecol. 2015; 22(2)285-90.

49 Salim S et al. Diagnosis and Management of Endometrial Polyps: A Critical Review of the Literature. J Minim Invasive Gynecol. 2011; 18(5):569-81.

50 MyoSure® Instructions for Use. Bedford, MA: Hologic, Inc.

51 Siddle N, et al. The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil Steril. 1987; 47:94-100.

52 Brand A, Bruinsma A, Van Groeningen K, Kalmijn S, Kardolus I, Peerden M, Smeenk R, De Swart S, Kurver M, Goudswaard L. NHG-Standaard Anticonceptie.

53 Federatie Medisch Specialisten. Richtlijnendatabase. Sterilisatie van de vrouw, algemeen (bezocht op 16-07-2019).

54 Lynne S. Wilcox, Beverty Martinez-Schnell, Herbert B. Peterson, James H. Ware, Joyce M. Hughes, Menstrual Function after Tubal Sterilization, American Journal of Epidemiology, Volume 135, Issue 12, 15 June 1992, Pages 1368–1381,

55 NVOG-richtlijn nr. 30 juli 2000. Sterilisatie bij de vrouw. Pagina 5, paragraaf 2.4 Langetermijneffecten van sterilisatie.

56 Parsanezhad ME, Alborzi SA, Namavar Jahrom B. Menstrual Abnormalities and Pain after Five Tubal Sterilization Methods: A Randomized Controlled Trial. IJMS Vol 28, No.2, June 2003.

57 Rochelle N. Shain, Ph.D. Warren B. Miller, M.D. George W. Mitchell, M.D.  Alan E. C. Holden, M.A. II Marc Rosenthal, Ph.D. Menstrual pattern change 1 year after sterilization: results of a controlled, prospective study. The American Fertility Society Vol. 52, No.2, August 1989.

58 Jonathan R. Bull, Simon P. Rowland, Elina Berglund Scherwitzl, Raoul Scherwitzl, Kristina Gemzell Danielsson & Joyce Harper. Real-world menstrual cycle characteristics of more than 600,000 menstrual cycles. NPJ Digital Medicine volume 2, Article number: 83 (2019).

59 Dekker, H. J., Boeke, P. J., Gercama, J. A., Kardolus, J. G., & Boukes, S. F. (2009). NHG-standaard Fluor vaginalis. In NHG-Standaarden 2009 (pp. 624-636). Springer.

60 NHG-Standaard Pelvic inflammatory disease, Samenvattingskaart M50 (2005),

61, (bezocht op 16-9-2019).

62 Donnez J, Dolmans P. Uterine fibroid management: from the present to the future. Hum Reprod Update 2016;22(6):665-686.

63 Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol. 1994;83:414–418.

64 Leibsohn S, d’Ablaing G, Mishell DR, Jr, et al. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obst Gynecol. 1990;162:968–974. doi: 10.1016/0002-9378(90)91298-Q.

65 Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol. 2012 Jul 25;358(2):223-31. doi: 10.1016/j.mce.2011.05.044

66 Islam MS, et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab. 2013 Mar;98(3):921-34. doi: 10.1210/jc.2012-3237

67 Vlahos NF, Theodoridis TD, Partsinevelos GA. Myomas and Adenomyosis: Impact on Reproductive Outcome. BioMed Res Int. 2017.

68 Mutch DG, Biest SW. (2019). Fibroids. Retrieved from MSD Manual Consumer Version: (Accessed: 6 April 2020)

69 Proctor M, Farquhar C. Dysmenorrhoea. Clin Evid 2003; 10:2058-78

70 Folmer, H. (2004) NHG Farmacotherapeutische richtlijn Dysmenorroe. Geraadpleegd op: 14 April 2020.

71 Marjoribanks J, Proctor ML, Farquhar C. Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea (Cochrane review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley &Sons, Ltd.

72 Dawood MY. Dysmenorrhea. Clin Obstet Gynecol 1990; 33: 168-78.

73 Shapiro SS. Treatment of dysmenorrhoea and premenstrual syndrome with non-steroidal anti-inflammatory drugs. Drugs 1988; 88: 475-90.

74 Ozgoli G, Goli M, Moattar F. Comparison of effects of ginger, mefenamic acid, and ibuprofen on pain in women with primary dysmenorrhea. J Alt Compl Med. 2009;15(2). doi:

75 Van Asselt KM, Bruinsma ACA, Engelsman N, Hammers-Cupido RJ, Landskröner I, Opstelten W, De Vries CJH. NHG-Standaard Miskraam (derde herziening).

76 NHG-werkgroep Amenorroe. NHG-Standaard Amenorroe (derde herziening).

77 Dekker JH, Veehof LJG, Hinloopen RJ, Van Kessel T, Boukes FS.  NHG-Standaard Pelvic inflammatory disease (Eerste herziening). Huisarts Wet 2005;48(10):509-13.

 78 Butler Tobah, Yvonne. “Is implantation bleeding normal in early pregnancy?” Mayo Foundation for Medical Education and Research, 9 May 2019. Web. 29 Apr. 2020

79, Symptomen bij baarmoederkanker (bezocht op 29-04-2020).

 80, Vaginakanker (bezocht op 29-04-2020).

 81, Tamoxifen (bezocht op 29-04-2020)

 82 Aarts JWM, Nieboer TE, Johnson N, Tavender E, Garry R, Mol BJ, Kluivers KB. Surgical approach to hysterectomy for benign gynaecological diseases. Cochrane Database of Systematic Reviews 2015, Issue 8. Art. No.: CD003677. doi: 10.1002/14651858.CD003677.pub5.

83 Ramdhan RC, Loukas M, R Shane Tubbs. Anatomical complications of hysterectomy: a review. Clin. Anat. 30:946-952, 2017.

84 Ferri FF. Pelvic organ prolapse (uterine prolapse). In: Ferri’s Clinical Advisor 2017. Philadelphia, Pa.: Elsevier; 2017. Geraadpleegd 13 April 2020.

85 Hofmeister S, Bodden S. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician. 2016 Aug 1;94(3):236-240.

86 Federatie Medisch Specialisten. “Premenstrueel syndroom (PMS)” Nederlandse Vereniging voor Obstetrie en Gynaecologie, 1 jan. 2012. Web. 19 mei 2020.

87 Mishell DR Jr. Premenstrual disorders: epidemiology and disease burden. Am J Manag Care. 2005;11(16 suppl):S473–S479.

88 Lukes, A.S., McBride, R.J., Herring, A.H., Fried, M., Sherwani, A., Dell, D. (2011). Improved premenstrual syndrome symptoms after NovaSure endometrial ablation. The Journal of Minimally Invasive Gynaecology. September–October, 2011, Volume 18, Issue 5, Pages 607–611.

89 Scordalakes, C., delRosario, R., Shimer, A., Stankiewicz, R. (2018). Efficacy and patient satisfaction after NovaSure and Minerva endometrial ablation for treating abnormal uterine bleeding: a retrospective comparative study. International Journal of Women’s Health. 18 April 2018 Volume 2018:10 Pages 137—145.

90 Waddell, G., Pelletier, J., Desindes, S., Anku-Bertholet, C., Blouin, S., Thibodeau, D. (2015). Effect of endometrial ablation on premenstrual symptoms. The Journal of Minimally Invasive Gynaecology. May-June, 2015, Volume 22, Issue 4, Pages 631-36.

91 Bouma J, De Jonge M, De Laat EAT, Eekhof H, Engel F, Groeneveld FPMJ, Stevens NTJM, Verduijn MM, Goudswaard AN, Opstelten W, De Vries CJH. NHG-De overgang. Versie 2.0, april 2012.

92 Bouma M, Burgers J, Drost B, Den Elzen WPJ, Luchtman T, Oosterhuis WP, Woutersen-Koch H, Van Wijk M. NHG-Standaard Anemie. Versie 2.0, oktober 2014.

93 Voedingscentrum. “IJzer” Web. 12 Januari 2021.

94 Huisarts en Wetenschap, Onverwachte gevolgen van endometriumablatie (bezocht op 2-3-2023).

Op zoek naar een gespecialiseerd ziekenhuis in de omgeving?